Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SD-101
SD-101
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Yahoo
Mon, 10/13/14 - 07:26 am
Dynavax
TLR-9
immuno-oncology
B-cell lymphoma
SD-101
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Mon, 08/26/13 - 01:28 pm
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
